In conclusion, the current MRGPS consisting of NOP2, NSUN6, and TET2 is a potential alternative prognostic biomarker for ccRCC patients and is also be a promising index for personalized ICI treatments in ccRCC. This evidence concerns the gene NSUN6 and nonpapillary renal cell carcinoma.